Researchers identify real-world barriers to evolocumab adherence
Cost, concerns over a lack of long-term clinical data, and injection fear were the top reasons cited for nonadherence to evolocumab therapy, according to a small study assessing the real-world barriers among patients with coronary artery disease (CAD). [Pandey AK, et al, AHA 2017, abstract T2134]
In the single-centre retrospective study of 116 high-risk patients with stable CAD who had experienced MI or undergone revascularization, cost was the primary reason cited by 68 percent of patients as the reason why they failed to initiate evolocumab treatment. Little long-term clinical data and injection fear (72 and 28 percent of the remaining patients, respectively) were also primary barriers.
The researchers followed patients for 1 year regardless of whether they initiated or adhered to therapy. Patients who initiated and adhered to evolocumab on top of statin therapy showed significant, sustained cholesterol improvements – a 56 percent LDL-cholesterol reduction compared with no significant cholesterol change in the control group. Neither group had serious adverse events.